An interesting stock that came up in some of our conversations today is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS). At current price of $4.13, the shares have already lost -0.27 points (-6.08% lower) from its previous close of $4.4. Should you buy or avoid them? The stock sets an active trading volume day with a reported 121789 contracts so far this session. CRVS shares had a relatively better volume day versus average trading capacity of 216.2 thousand shares, but with a 24.4 million float and a -15.71% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CRVS stock indicates that the average analyst price target is $11 per share. This means the stock has a potential increase of 166.34% from where the CRVS share price has been trading recently.
During the recent trading session for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), the company witnessed their stock drop by $-0.66 over a week and tumble down $-1.17 from the price 20 days ago. When compared to their established 52-week high of $8.1, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 05/07/19. The recent low of $2.53 stood for a -48.98% since 03/10/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.28 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Corvus Pharmaceuticals, Inc., the two-week RSI stands at 38.65. This figure suggests that CRVS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current CRVS readings is similarly very revealing as it has a stochastic reading of 16% at this stage. This figure means that CRVS share price today is being overbought.
Technical chart claims that Corvus Pharmaceuticals, Inc. (CRVS) would settle between $4.68/share to $4.97/share level. However, if the stock price goes below the $3.93 mark, then the market for Corvus Pharmaceuticals, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $3.47 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.43. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Mizuho, assumed coverage of CRVS assigning Buy rating, according to their opinion released on September 12. ROTH Capital, analysts launched coverage of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock with a Buy recommendation, according to their flash note issued to investors on May 29. Analysts at Credit Suisse released an upgrade from Underperform to Neutral for the stock, in a research note that dated back to August 24.
CRVS equity has an average rating of 1.5, with the figure leaning towards a bullish end. 3 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 3 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 3 analysts rated Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.